Condition: Non-Alcoholic Fatty Liver Disease · Type 2 Diabetes · Mitochondrial Metabolism Disorders · Sponsor: The University of Texas Health Science Center at San Antonio
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
This description comes directly from the study's public registry record.
Luke Norton, PhD · 210-567-0739 · nortonl@uthscsa.edu
Andrea Hansis-Diarte, MPH · 210-567-3208 · hansisdiarte@uthscs.edu
Always discuss trial participation with your own doctor first.
| Texas Diabetes Institute - University Health System | San Antonio, Texas, United States | Recruiting |
| University of Texas Health Science Center at San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05305287